LeonaBio (LONA) Liabilities and Shareholders Equity (2019 - 2026)

LeonaBio (LONA) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $71.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 64.53% year-over-year to $71.6 million; the TTM figure through Mar 2026 stood at $229.3 million (down 23.51% YoY), while the FY2025 annual figure was $92.2 million, up 56.78% from the prior year.
• Liabilities and Shareholders Equity retreated to $71.6 million in Q1 2026 per LONA's latest filing, from $92.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $313.0 million in Q1 2022 and bottomed at $30.0 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $152.1 million across 5 years, with a median of $133.5 million in 2024.
• Annual changes were most pronounced in 2025 — Liabilities and Shareholders Equity plunged 68.05% — and 2026, when it soared 64.53%.
• LeonaBio's Liabilities and Shareholders Equity stood at $258.2 million in 2022, then slumped by 37.93% to $160.2 million in 2023, then sank by 63.32% to $58.8 million in 2024, then jumped by 56.78% to $92.2 million in 2025, then declined by 22.31% to $71.6 million in 2026.
• Business Quant data shows LONA's Liabilities and Shareholders Equity at $71.6 million in Q1 2026, $92.2 million in Q4 2025, and $30.0 million in Q3 2025.